Eikon Therapeutics is no stranger to eye-popping funding rounds, and the cancer-focused biotech has continued this trend with ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

Idorsia, which is no stranger to needing to find cash quickly, also said it has raised 150 million Swiss francs ($167 million ...

Clinical trial matchmaker myTomorrows has struck up a partnership with personal health recordkeeper Patients Know Best (PKB) ...

Quest Diagnostics will take over the kidney-focused lab testing portfolio of the dialysis giant Fresenius Medical ...

AV0328, one of Alopexx’s lead candidates, is a synthetic PNAG vaccine that has completed a phase 1 trial. The biotech is ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...

The wearable cardiac monitor and defibrillator developer Kestra Medical Technologies aims to raise about $154 million by ...

With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...

For the last six weeks, the shadow of potential layoffs has hung over Repare Therapeutics’ employees. Monday, staff learned ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...